Toxoplasmosis, a cosmopolitan anthropozoonosis widespread in mammals and birds normally asymptomatic in healthy subjects, it can have serious consequences for the fetus in the first trimester of pregnancy and in the immunocompromised subject [1]. The prevalence of toxoplasmosis is heterogeneous and varies by country. In Europe it varied by country: 19% - 29% in Spain [2], 24% in Greece [3], 55% of pregnant women in France [4]. In Africa, it was 34.1% among pregnant women in Sudan [5], 47.9% among pregnant women in the Central African Republic in 2016 [6], 81% in Gabon, 78% in Nigeria and 60% in Côte d'Ivoire [7]. Transmission in humans is by ingestion of cyst contained in the cooked meats and oocysts eliminated by the definitive host in nature soiling water and food. Transmission can also occur from the mother to the child causing severe congenital toxoplasmosis with various malformations and late onset ocular lesions. The risk of maternal-fetal transmission of congenital toxoplasmosis increases with the age of pregnancy at the time of maternal infection, Toxoplasma gondii infection is responsible for severe encephalitis in nearly 40% of patients with acquired immunodeficiency syndrome (AIDS) and causes the death of about a third of these patients [8]. Toxoplasmosis is one of the most common congenital infections in the world [9]. It poses a significant threat, especially in early pregnancy, to the fetus because of the severity of the in utero manifestations and the devastating consequences for the infant. There is no vaccine to control this infection. It is in this context and in order to suggest a specific prevention programme that it seems appropriate to assess the immune to T. gondii in pregnant women in Central African Republic.

Toxoplasmic infection is one of the most common congenital infections in the world. It poses a significant threat, especially in early pregnancy, to the fetus because of the severity of the in utero manifestations and the devastating consequences for the infant. The risk of congenital toxoplasmosis is often higher in co-infected HIV-Toxoplasmosis mothers than in monoinfected toxoplasmosis-only mothers [10]. The average age of our patients was 28 ± 6 years in this study. These results are similar to some previous work [11]. The seroprevalence of toxoplasmosis was 14.65% during this work. This seroprevalence was non-significantly high (p = 0.96) in the 20 - 24 year age group (24.42%) and in the paucipares (40.71%). These results corroborate those of some authors [11] who had previously shown that the seroprevalence of toxoplasmosis in pregnant women varied by socio-demographic characteristics [11] [12]. This age variation was an expected outcome for an immunizing condition. Differences in the residence of seroprevalence observed in this study were already reported by some authors [11] [13]. This disparity could be explained by differences in dietary behaviour depending on the location of the residence where seroprevalence would be correlated to the temperate and humid climate promoting oocyst conservation in the soil [13]. Our study showed lower proportions of IgM and IgG antibodies anti T. gondii in pregnant women with a significant difference (p = 0.018) by age group but not statistically significant by parity (p = 0.23). Our results differ from those obtained in previous work where the authors had shown much higher proportions [14]. This difference between our results could likely be due to the use of the indirect haemagglutination technique which could lead to misinterpretation and lead to an underestimation of seroprevalence. This is a limitation in this study. Similarly, the study population differs from that used in some studies [6]. Furthermore, depending on the immune status, immune and non-immune women are equally exposed to toxoplasmic infection [OR = 0.97; CI 95% = 0.46 - 2.05]. These results assumed that pregnant women, residing in the environment where the parasite circulates, are exposed to recurrent infection, reinfection or even reactivation of a chronic T. gondii infection. Nevertheless, many of the studies have shown that congenital toxoplasmosis due to reactivation of maternal infection is less common than that usually observed [15] [16] [17]. In addition, our results showed that women with HIV-positive serology appeared to be exposed to toxoplasmic infection. Our results are in line with those obtained in previous work where the authors showed varying proportions in Congo [18] and Burkina Faso [19] in HIV-infected subjects. However, the proportion of vertical transmission of T. gondii infection in pregnant HIV+ infected women previously exposed to T. gondii is not yet well defined. Nevertheless, many of the studies have shown that congenital toxoplasmosis due to reactivation of maternal infection is less common than that usually observed [15].

Toxoplasmosis remains particularly serious during pregnancy. Seroprevalence of Toxoplasma gondii infection was lower in this study. It was also significantly higher in the 20 - 24 age group. There was no significant difference between urban and semi-urban areas. Women were similarly exposed depending on whether they were immunized or not. This requires the establishment of a specific prevention program against this disease.

WSN conceived, designed, conducted the experiments, analyzed the data and prepared the manuscript. JON read and approved the final manuscript. GA collected the data and REKL read and approved the final manuscript.

No funding received.

This study protocol received full approval from the local Ethics committee of Health Science Faculty of University of Bangui and was conducted in compliance with the declaration of Helsinki. Approval reference number 18/FACSS/CES/21.

Data is contained within the article.

The authors declare no conflicts of interest regarding the publication of this paper.

Nambei, W.S., Nguerenam Jr., O., Kodia-Lenguetama, E.R. and Gbamonza, A. (2022) Humoral Response to Toxoplasma gondii in Pregnant Women in Bangui Central African Republic. Open Journal of Immunology, 12, 122-129. https://doi.org/10.4236/oji.2022.124008